Viz.ai has announced a strategic partnership with Alnylam Pharmaceuticals aimed at improving the early detection and diagnosis of cardiac amyloidosis, a serious and often underdiagnosed cause of heart failure.
Cardiac amyloidosis is a progressive condition characterized by the buildup of misfolded proteins in the heart muscle, which can lead to severe cardiac dysfunction and poor outcomes if left untreated. The disease primarily presents in two forms: transthyretin amyloid cardiomyopathy (ATTR-CM), which can be hereditary or age-related, and light chain (AL) amyloidosis. Despite advancements in treatment, many patients remain undiagnosed or are diagnosed only after significant delays due to vague symptoms and fragmented care pathways.
The collaboration between Viz.ai and Alnylam seeks to address these challenges by leveraging artificial intelligence to identify patients earlier in the disease course and streamline diagnostic workflows. As part of the initiative, Viz.ai will develop a dedicated AI-powered Care Pathway for cardiac amyloidosis. This solution is designed to assist clinicians in recognizing potential cases sooner and guiding them through standardized, evidence-based diagnostic steps.
According to Tim Showalter, delayed diagnosis can have serious consequences for patients with cardiac amyloidosis. He noted that integrating advanced imaging analysis with generative AI and care coordination tools could help clinicians detect high-risk patients earlier and initiate timely interventions.
The Care Pathway will utilize an FDA-cleared echocardiography AI algorithm, Us2.ai, combined with electronic health record (EHR) connectivity. This system will automatically analyze routine echocardiograms, flag patients with suspicious clinical indicators, and facilitate coordinated follow-up actions such as confirmatory testing and specialist referrals. By embedding these capabilities into clinical workflows, the platform aims to reduce variability in care and improve decision-making consistency.
Sameer Bansilal emphasized that patients with ATTR-CM are frequently diagnosed late, often after years of disease progression. He highlighted that the partnership brings AI-driven insights into everyday clinical practice, enabling earlier recognition and faster initiation of appropriate diagnostic and treatment pathways.
The new Viz Cardiac Amyloidosis Care Pathway will initially be evaluated through a multi-site pilot study. The study will assess how effectively the solution integrates into clinical workflows and its impact on key outcomes such as diagnostic rates, time to treatment, and care coordination.
This initiative builds on the broader Viz platform, which is already deployed in approximately 2,000 hospitals across the United States. By expanding its Viz Cardio Suite™, the company aims to further enhance access to timely, life-saving care while supporting healthcare providers in managing complex cardiovascular conditions more efficiently.
For Alnylam, the partnership aligns with its broader mission to transform care for patients with ATTR-CM by promoting earlier diagnosis and more coordinated, scalable treatment approaches.